메뉴 건너뛰기




Volumn 8, Issue 3, 2007, Pages 132-144

Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy

Author keywords

AIDS; HAART; HIV; NHL; Rituximab

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; NUCLEOSIDE ANALOG; PREDNISONE; PROTEINASE INHIBITOR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINCRISTINE;

EID: 34547185564     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0803-132     Document Type: Article
Times cited : (13)

References (35)
  • 1
    • 8244234470 scopus 로고    scopus 로고
    • Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group
    • Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(23):1641-1648.
    • (1997) N Engl J Med , vol.336 , Issue.23 , pp. 1641-1648
    • Kaplan, L.D.1    Straus, D.J.2    Testa, M.A.3
  • 2
    • 34547229388 scopus 로고    scopus 로고
    • Effect of individual HAART treatment on Hodgkin and non-Hodgkin lymphoma risk among HIV patients
    • Dal Maso L, Clifford G, Polesel J, Franceschi S, Rickenbach M. Effect of individual HAART treatment on Hodgkin and non-Hodgkin lymphoma risk among HIV patients. Ann Oncol. 2005;16(Suppl 5):v28a.
    • (2005) Ann Oncol , vol.16 , Issue.SUPPL. 5
    • Dal Maso, L.1    Clifford, G.2    Polesel, J.3    Franceschi, S.4    Rickenbach, M.5
  • 3
    • 0036500980 scopus 로고    scopus 로고
    • Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia
    • Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492-1499.
    • (2002) Cancer , vol.94 , Issue.5 , pp. 1492-1499
    • Cortes, J.1    Thomas, D.2    Rios, A.3
  • 4
    • 0035895086 scopus 로고    scopus 로고
    • Autologous stem cell transplantation for HIV-associated lymphoma
    • Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood. 2001;98(13):3857-3859.
    • (2001) Blood , vol.98 , Issue.13 , pp. 3857-3859
    • Krishnan, A.1    Molina, A.2    Zaia, J.3
  • 5
    • 22344450861 scopus 로고    scopus 로고
    • AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy
    • Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430-4438.
    • (2005) J Clin Oncol , vol.23 , Issue.19 , pp. 4430-4438
    • Lim, S.T.1    Karim, R.2    Nathwani, B.N.3    Tulpule, A.4    Espina, B.5    Levine, A.M.6
  • 6
    • 85112378864 scopus 로고    scopus 로고
    • HIV-related lymphoma: Changes in immune parameters and viral load during chemotherapy
    • Weiss R, Mitrou P, Arasteh K, Schurmann D, Huhn D. HIV-related lymphoma: changes in immune parameters and viral load during chemotherapy. Blood. 2000;96(11):134a.
    • (2000) Blood , vol.96 , Issue.11
    • Weiss, R.1    Mitrou, P.2    Arasteh, K.3    Schurmann, D.4    Huhn, D.5
  • 7
    • 0035902947 scopus 로고    scopus 로고
    • Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy
    • Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS. 2001;15(12):1483-1491.
    • (2001) AIDS , vol.15 , Issue.12 , pp. 1483-1491
    • Antinori, A.1    Cingolani, A.2    Alba, L.3
  • 8
    • 0035889139 scopus 로고    scopus 로고
    • Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy
    • Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339-2344.
    • (2001) Blood , vol.98 , Issue.8 , pp. 2339-2344
    • Besson, C.1    Goubar, A.2    Gabarre, J.3
  • 9
    • 0035072134 scopus 로고    scopus 로고
    • Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART)
    • Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leukemia Lymphoma. 2001;41(1 -2):105-116.
    • (2001) Leukemia Lymphoma , vol.41 , Issue.1 -2 , pp. 105-116
    • Chow, K.U.1    Mitrou, P.S.2    Geduldig, K.3    Helm, E.B.4    Hoelzer, D.5    Brodt, H.R.6
  • 10
    • 0035760292 scopus 로고    scopus 로고
    • Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy [comment]
    • Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy [comment]. Blood. 2001;98(12):3406-3412.
    • (2001) Blood , vol.98 , Issue.12 , pp. 3406-3412
    • Kirk, O.1    Pedersen, C.2    Cozzi-Lepri, A.3
  • 11
    • 0034667530 scopus 로고    scopus 로고
    • Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
    • Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730-2734.
    • (2000) Blood , vol.96 , Issue.8 , pp. 2730-2734
    • Matthews, G.V.1    Bower, M.2    Mandalia, S.3    Powles, T.4    Nelson, M.R.5    Gazzard, B.G.6
  • 12
    • 0037342949 scopus 로고    scopus 로고
    • Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy
    • Navarro JT, Ribera JM, Oriol A, Tural C, Milla F, Feliu E. Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;32(3):347-348.
    • (2003) J Acquir Immune Defic Syndr , vol.32 , Issue.3 , pp. 347-348
    • Navarro, J.T.1    Ribera, J.M.2    Oriol, A.3    Tural, C.4    Milla, F.5    Feliu, E.6
  • 13
    • 0005376590 scopus 로고    scopus 로고
    • Highly active antiretroviral therapy (HAART) significantly improves disease free survival (DFS) in patients (pts) with HIV-related non-Hodgkin's lymphoma (HIV-NHL) treated with chemotherapy (CT)
    • Vaccher E, di Gennaro G, Shioppa O, et al. Highly active antiretroviral therapy (HAART) significantly improves disease free survival (DFS) in patients (pts) with HIV-related non-Hodgkin's lymphoma (HIV-NHL) treated with chemotherapy (CT). Proc ASCO. 2001;20(2):294a.
    • (2001) Proc ASCO , vol.20 , Issue.2
    • Vaccher, E.1    di Gennaro, G.2    Shioppa, O.3
  • 14
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
    • (2002) N Engl J Med , vol.346 , Issue.4 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 15
    • 24644500086 scopus 로고    scopus 로고
    • Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
    • Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033.
    • (2005) J Clin Oncol , vol.23 , Issue.22 , pp. 5027-5033
    • Sehn, L.H.1    Donaldson, J.2    Chhanabhai, M.3
  • 16
    • 23944508056 scopus 로고    scopus 로고
    • Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
    • Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543.
    • (2005) Blood , vol.106 , Issue.5 , pp. 1538-1543
    • Kaplan, L.D.1    Lee, J.Y.2    Ambinder, R.F.3
  • 17
    • 2342635848 scopus 로고    scopus 로고
    • Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group Trial (E1494)
    • Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol. 2004;22(8):1491-1500.
    • (2004) J Clin Oncol , vol.22 , Issue.8 , pp. 1491-1500
    • Sparano, J.A.1    Lee, S.2    Chen, M.G.3
  • 18
    • 20144367599 scopus 로고    scopus 로고
    • Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials
    • Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891-1897.
    • (2005) Blood , vol.105 , Issue.5 , pp. 1891-1897
    • Spina, M.1    Jaeger, U.2    Sparano, J.A.3
  • 19
    • 0035397512 scopus 로고    scopus 로고
    • Human immunodeficiency virus-related non-Hodgkin lymphoma: Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients
    • Spina M, Vaccher E, Juzbasic S, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer. 2001;92(1):200-206.
    • (2001) Cancer , vol.92 , Issue.1 , pp. 200-206
    • Spina, M.1    Vaccher, E.2    Juzbasic, S.3
  • 21
    • 0030666522 scopus 로고    scopus 로고
    • Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: Natural history of relapse after initial complete response and prognostic variables defining outcome after relapse
    • Hoskins PJ, Le N, Gascoyne RD, et al. Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. Ann Oncol. 1997;8(11):1125-1132.
    • (1997) Ann Oncol , vol.8 , Issue.11 , pp. 1125-1132
    • Hoskins, P.J.1    Le, N.2    Gascoyne, R.D.3
  • 22
    • 0026097554 scopus 로고
    • MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease
    • O'Reilly SE, Hoskins P, Klimo P, Connors JM. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol. 1991;2(Suppl 1):17-23.
    • (1991) Ann Oncol , vol.2 , Issue.SUPPL. 1 , pp. 17-23
    • O'Reilly, S.E.1    Hoskins, P.2    Klimo, P.3    Connors, J.M.4
  • 23
    • 0345334246 scopus 로고    scopus 로고
    • Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA
    • Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276(2):146-154.
    • (1996) JAMA , vol.276 , Issue.2 , pp. 146-154
    • Carpenter, C.C.1    Fischl, M.A.2    Hammer, S.M.3
  • 24
    • 0033458716 scopus 로고    scopus 로고
    • The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma
    • Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer. 1999;86(11):2391-2397.
    • (1999) Cancer , vol.86 , Issue.11 , pp. 2391-2397
    • Rossi, G.1    Donisi, A.2    Casari, S.3    Re, A.4    Cadeo, G.5    Carosi, G.6
  • 25
    • 23644432624 scopus 로고    scopus 로고
    • A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy
    • Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143(4):265-273.
    • (2005) Ann Intern Med , vol.143 , Issue.4 , pp. 265-273
    • Bower, M.1    Gazzard, B.2    Mandalia, S.3
  • 26
    • 4344613254 scopus 로고    scopus 로고
    • No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: Updated data from AIDS malignancies consortium study 010
    • Kaplan LD, Lee J, Scadden DT. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: updated data from AIDS malignancies consortium study 010. Blood. 2003;102(11):409-410a.
    • (2003) Blood , vol.102 , Issue.11
    • Kaplan, L.D.1    Lee, J.2    Scadden, D.T.3
  • 27
    • 0027394689 scopus 로고
    • Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
    • Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002-1006.
    • (1993) N Engl J Med , vol.328 , Issue.14 , pp. 1002-1006
    • Fisher, R.I.1    Gaynor, E.R.2    Dahlberg, S.3
  • 28
    • 9044226138 scopus 로고    scopus 로고
    • Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen
    • Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925-934.
    • (1996) J Clin Oncol , vol.14 , Issue.3 , pp. 925-934
    • Magrath, I.1    Adde, M.2    Shad, A.3
  • 29
    • 33748657979 scopus 로고    scopus 로고
    • Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
    • Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(25):4123-4128.
    • (2006) J Clin Oncol , vol.24 , Issue.25 , pp. 4123-4128
    • Boue, F.1    Gabarre, J.2    Gisselbrecht, C.3
  • 30
    • 13644249821 scopus 로고    scopus 로고
    • Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update
    • Habermann TM, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood. 2004;104(11):40a.
    • (2004) Blood , vol.104 , Issue.11
    • Habermann, T.M.1    Weller, E.2    Morrison, V.A.3
  • 31
    • 33645504592 scopus 로고    scopus 로고
    • The case for rituximab in AIDS-related lymphoma
    • Dunleavy K, Wilson WH, Kaplan LD. The case for rituximab in AIDS-related lymphoma. Blood. 2006;107(7):3014-3015.
    • (2006) Blood , vol.107 , Issue.7 , pp. 3014-3015
    • Dunleavy, K.1    Wilson, W.H.2    Kaplan, L.D.3
  • 32
    • 0033572954 scopus 로고    scopus 로고
    • AIDS-related opportunistic illnesses occurring after initiation of potent anti-retroviral therapy: The Swiss HIV Cohort Study [comment]
    • Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent anti-retroviral therapy: the Swiss HIV Cohort Study [comment]. JAMA. 1999;282(23):2220-2226.
    • (1999) JAMA , vol.282 , Issue.23 , pp. 2220-2226
    • Ledergerber, B.1    Egger, M.2    Erard, V.3
  • 33
    • 0030727417 scopus 로고    scopus 로고
    • Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient
    • Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS. 1997;11(15):1895- 1896.
    • (1997) AIDS , vol.11 , Issue.15 , pp. 1895-1896
    • Weir, A.1    Wansbrough-Jones, M.2
  • 35
    • 23244448555 scopus 로고    scopus 로고
    • Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: Case report and literature review
    • Motl SE, Baskin RC. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy. 2005;25(8):1151-1155.
    • (2005) Pharmacotherapy , vol.25 , Issue.8 , pp. 1151-1155
    • Motl, S.E.1    Baskin, R.C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.